Pulmonary Embolism
New dyspnea, pleuritic pain, hypoxemia, tachycardia, syncope or unexplained deterioration after pelvic surgery warrants assessment for PE alongside bleeding, pneumonia, atelectasis, myocardial disease and sepsis. Neither a normal oxygen saturation nor an alternative plausible postoperative diagnosis excludes PE. The immediate priorities are recognition of shock, objective diagnosis when feasible, and a treatment plan that accounts for the operative bleeding site.[1]
See also: Antithrombotic Therapy for prevention, interruption and neuraxial timing, and Anticoagulation Reversal for major bleeding. Prophylactic doses do not treat an established PE.
Epidemiology and Presentation
PE affects roughly 370,000 patients a year in the United States (incidence 60–120 per 100,000 person-years) and causes an estimated 60,000–100,000 deaths annually.[1] Most emboli arise from the deep veins of the legs and pelvis. Stasis, hypercoagulability and endothelial injury contribute to VTE after major pelvic surgery. Symptomatic postoperative VTE occurs during the first week and continues through at least week four; assess compatible symptoms whenever they arise.[24] The embolus raises pulmonary vascular resistance and RV afterload and lowers LV preload; a large clot burden precipitates hemodynamic collapse.[1]
Dyspnea, pleuritic pain, tachycardia and hypoxemia are the common features; hemoptysis is uncommon and syncope or shock signals a large embolus. After cystectomy, nephrectomy or other pelvic reconstruction, the same symptoms are shared by atelectasis, pneumonia, volume overload, transfusion-related lung injury and sepsis from an anastomotic leak, and they often coexist.[1] Only a minority of patients evaluated for suspected PE turn out to have it.[1]
Diagnostic Approach
Establish Probability Before Ordering D-Dimer
Use a validated pathway based on clinical probability, assessed by an appropriate score or experienced clinical judgment. Wells (dichotomized: PE unlikely at ≤4 points, likely at >4) and revised Geneva are alternatives. In a patient with high probability or circulatory deterioration, do not delay imaging or emergency assessment to obtain a D-dimer.[1][2]
PERC is an option only when the initial probability is low and all eight criteria are negative: age under 50, pulse under 100, oxygen saturation at least 95%, no unilateral leg swelling, hemoptysis, prior VTE, estrogen use, or qualifying recent surgery or trauma.[25] The recent-surgery or trauma criterion applies when the event required endotracheal intubation or hospitalization within four weeks; assess the oxygen saturation criterion on room air.[25]
D-dimer is useful for exclusion within validated low- or intermediate-probability pathways, not for confirming PE. A positive result is common after surgery, with cancer and during hospitalization. Match the cutoff to the assay and units; the standard 500 ng/mL FEU cutoff is not interchangeable with a DDU value. Age-adjustment uses age × 10 ng/mL FEU above age 50. YEARS instead uses three items (clinical signs of DVT, hemoptysis, PE the most likely diagnosis): with none, PE is excluded by a D-dimer below 1,000 ng/mL; with one or more, below 500 ng/mL. In the prospective YEARS cohort, symptomatic VTE occurred within three months in 18/2,946 (0.61%) untreated patients after PE was ruled out; CTPA was not indicated in 1,651/3,465 (48%) assessed patients.[16] Do not mix algorithms.[2][3][4][16]
Postoperative elevation reduces D-dimer efficiency; no fixed two-week interval invalidates a negative result. ADJUST-PE included some patients with recent surgery, although it studied emergency-department outpatients. Choose a validated pathway for the actual setting; high probability proceeds to imaging.[3]
Imaging
CT pulmonary angiography is the usual definitive test. V/Q imaging is an alternative when contrast or other patient factors favor it and a diagnostic study is obtainable. Proximal venous ultrasound may establish VTE when chest imaging is impractical; an isolated distal calf finding requires its own interpretation. Bedside echocardiography can identify RV failure and competing causes in an unstable patient but a normal study does not exclude PE.[1][2] For suspected category C2-or-higher PE with low bleeding risk, therapeutic anticoagulation may be beneficial if imaging is delayed or unavailable (2026 guideline, Class 2a, Level C-EO).[2]
Severity and Disposition
Assess blood pressure and perfusion, oxygen or support requirements, RV findings, biomarkers, comorbidity and trajectory. Normotension can coexist with shock.[2]
The 2026 AHA/ACC guideline introduces categories A–E:[2]
| Category | Clinical distinction |
|---|---|
| A | Incidentally detected, asymptomatic PE |
| B | Symptomatic PE with low clinical severity |
| C | Elevated clinical severity; subdivisions incorporate RV dysfunction and biomarkers |
| D | Incipient cardiopulmonary failure, including transient hypotension or normotensive shock |
| E | Cardiopulmonary failure with persistent/recurrent hypotension, refractory shock or arrest |
A respiratory modifier identifies additional respiratory compromise. Within category C, C1 is an elevated severity score with normal RV function and biomarkers, C2 adds either RV dysfunction or elevated biomarkers, and C3 has both. RV dysfunction is judged by echocardiography (dilatation, hypokinesis, septal bowing, McConnell sign) or a CT RV:LV ratio of at least 1.0, with troponin or natriuretic peptide as biomarkers. SBP ≥90 mmHg does not automatically mean a stable, low-risk patient.
A validated tool such as Hestia or PESI or sPESI, together with clinical assessment, can support outpatient treatment. sPESI scores one point each for age over 80, cancer, chronic cardiopulmonary disease, heart rate ≥110, systolic pressure below 100 mmHg and oxygen saturation below 90%; a score of 0 (category B) supports early discharge. Also establish bleeding risk, oral medication access, home support and reliable follow-up.[2] Patients with symptomatic category C–E PE should be hospitalized to optimize treatment.[2]
Anticoagulation
For most confirmed PE, anticoagulation is the foundation of treatment unless contraindicated. Select the agent using renal or hepatic function, bleeding, procedures, oral absorption, interactions and cancer status. For categories C1–E1 requiring initial parenteral treatment, the 2026 guideline recommends LMWH over UFH (Class 1, Level B-R). LMWH is also preferred after endovascular treatment or thrombolysis (Class 1, Level B-NR) and is reasonable when an endovascular procedure is anticipated (Class 2a, Level C-LD).[2] UFH remains useful when rapid interruption is needed or renal impairment is substantial.[2]
For suitable adults receiving oral treatment, two common labeled regimens are:[5][6]
| Drug | Initial PE treatment | Thereafter |
|---|---|---|
| Apixaban | 10 mg twice daily for 7 days | 5 mg twice daily [5] |
| Rivaroxaban | 15 mg twice daily for 21 days, with food | 20 mg once daily, with food [6] |
| Edoxaban | 5–10 days of parenteral anticoagulation first | 60 mg once daily; 30 mg if CrCl 15–50 mL/min, weight ≤60 kg or certain P-gp inhibitors [21] |
| Dabigatran | 5–10 days of parenteral anticoagulation first | 150 mg twice daily if CrCl >30 mL/min [22] |
Rivaroxaban labeling advises avoiding use when CrCl is below 15 mL/min.[6] Check the full label for renal or hepatic restrictions and interactions; do not apply atrial-fibrillation dose-reduction rules automatically to acute VTE.[2][5][6][21][22]
Cancer-associated PE can be treated with an appropriate DOAC or LMWH. GI or GU bleeding lesions, interactions, absorption and planned procedures matter. High-risk antiphospholipid syndrome, especially triple positivity, favors a vitamin K antagonist. Pregnancy requires a separate pathway.[2][5]
COBRRA: Acute Oral Treatment, 2026
In the 2,760-patient randomized COBRRA trial, clinically relevant bleeding over three months occurred in 44/1,345 apixaban recipients (3.3%) versus 96/1,355 rivaroxaban recipients (7.1%; RR 0.46, 95% CI 0.33–0.65).[7] This endpoint combined major and clinically relevant nonmajor bleeding. The primary abstract supports a bleeding advantage in the studied acute-VTE population; registered criteria excluded active cancer, CrCl below 30 mL/min and weight above 120 kg.[7][8]
Duration and Extended Treatment
Separate the initial 3–6-month treatment phase from the decision to continue. PE following a resolved major reversible factor, such as major surgery, often permits stopping after the initial phase. An unprovoked event or persistent risk factor may justify extended treatment after reassessing bleeding and preferences. Active cancer is persistent, not a strong transient provoking factor. Revisit the balance as cancer, mobility, renal function and bleeding change.[2]
Reduced-dose apixaban 2.5 mg twice daily or rivaroxaban 10 mg daily is an extended-phase option after at least six months of treatment.[5][6]
- API-CAT, 2025: 1,766 patients with active cancer who had already completed at least six months of anticoagulation were randomized to apixaban 2.5 versus 5 mg twice daily for a further year.[9] Recurrent VTE was 2.1% versus 2.8%, meeting the prespecified noninferiority criterion; clinically relevant bleeding was 12.1% versus 15.6%.[9] Recent major surgery within two weeks and several high-risk groups were excluded.[9][10]
- RENOVE, 2025: in 2,768 patients selected for extended anticoagulation, reduced-dose apixaban or rivaroxaban did not meet the noninferiority criterion versus full dose. Estimated five-year recurrent VTE was 2.2% versus 1.8% (HR 1.32, 95% CI 0.67–2.60); clinically relevant bleeding was lower with reduced dosing.[11]
Reperfusion and Escalation
Activate the local PE response or critical-care team for shock, deterioration, major RV failure or difficult bleeding-versus-treatment decisions. For PE-related cardiogenic shock (categories D2–E2), the 2026 guideline recommends vasopressors, inotropes, or both to improve cardiac output and systemic perfusion (Class 1, Level C-LD).[2] Reperfusion choices include systemic thrombolysis, catheter-directed thrombolysis, mechanical thrombectomy and surgical embolectomy; availability, severity and contraindications determine selection. VA-ECMO may provide support in selected refractory cases at experienced centers.[2][12] For acute PE categories C–E, avoid deep sedation and mechanical ventilation unless clinically indicated (Class 3: Harm, Level C-LD).[2] If sedation for intubation is required, have hemodynamic support with vasopressors, inotropes and/or VA-ECMO available (Class 1, Level C-LD).[2]
Systemic thrombolysis is not routine for every normotensive PE with RV strain. The 2026 guideline recommends against systemic lysis in categories A–C2 (Class 3: Harm), finds its benefit uncertain in C3, and allows consideration in D1–D2 (Class 2b).[2] With acceptable bleeding risk, systemic lysis is reasonable in E1–E2 (Class 2a); catheter-directed lysis and mechanical thrombectomy are reasonable in E1 (Class 2a) and may be considered in D1–D2 (Class 2b), but have no E2 recommendation.[2] It also recommends PERT assessment for categories C to E.[2] The labeled alteplase regimen for acute massive PE is 100 mg by IV infusion over 2 hours.[20] In PEITHO (1,005 normotensive patients with RV dysfunction and troponin elevation), tenecteplase reduced death or hemodynamic decompensation at 7 days (2.6% versus 5.6%) but raised major extracranial bleeding (6.3% versus 1.2%) and stroke (2.4% versus 0.2%, nearly all hemorrhagic); 30-day mortality did not differ statistically.[13] A meta-analysis of 15 trials found a mortality benefit that lost significance once high-risk PE trials were excluded, with more major (OR 2.91) and fatal or intracranial bleeding (OR 3.18).[17] Recent major surgery increases bleeding risk with systemic thrombolysis and requires weighing that risk against the anticipated benefit.[20] When advanced PE therapy is indicated, this may favor nonlytic mechanical thrombectomy or surgical embolectomy in a selected postoperative patient.[2]
Catheter-directed thrombolysis still administers a thrombolytic. Mechanical thrombectomy avoids a lytic but introduces vascular access, blood-loss and cardiopulmonary procedural risks. Neither approach is indicated simply because a clot is large.[2][12]
Two recent randomized trials of mechanical thrombectomy in intermediate-risk PE used surrogate or composite endpoints. In PEERLESS (550 patients), large-bore thrombectomy beat catheter-directed thrombolysis on a hierarchical win-ratio composite assessed at the sooner of discharge or 7 days (5.01), driven by less clinical deterioration or bailout (1.8% versus 5.4%) and less postprocedural ICU use, with no statistically significant differences in mortality, intracranial hemorrhage or major bleeding.[18] In STORM-PE (47 assigned thrombectomy and 53 anticoagulation alone), thrombectomy improved the 48-hour RV/LV ratio by 0.27 more than anticoagulation alone. Two PE-related deaths occurred in the thrombectomy arm and none in the control arm; the trial was not powered to establish differences in clinical events.[19]
HI-PEITHO: Selected Intermediate-Risk Patients, 2026
The open-label, blinded-adjudication HI-PEITHO trial randomized 544 patients with RV enlargement, elevated troponin and additional clinical severity features to ultrasound-facilitated catheter thrombolysis plus anticoagulation or anticoagulation alone. Seven-day PE-related death, decompensation or collapse, or symptomatic recurrent PE occurred in 11/273 (4.0%) versus 28/271 (10.3%); the difference was driven mainly by decompensation. Major bleeding within seven days in the treated population was 11/271 (4.1%) versus 6/271 (2.2%), a nonsignificant difference. This trial was published after the new guideline's release.[14]
The Postoperative Patient
There is no automatic rule that mandates a filter before 48 hours, LMWH until day 7, or a DOAC thereafter. Establish the actual bleeding site and hemostasis, drains, catheters, hemoglobin trend, renal function, planned reoperation and gastrointestinal function. Consult the operating and PE teams promptly; prophylaxis is not sufficient treatment while this decision is made.
If therapeutic anticoagulation is feasible, start an appropriate regimen with monitoring and a clear escalation plan. An oral transition requires reliable intake or absorption and a procedural plan. Coordinate every therapeutic dose with any neuraxial catheter using the antithrombotic workflow.
IVC filters: consider a retrievable filter when acute PE cannot be anticoagulated, with an explicit follow-up/removal plan. Do not add one routinely to effective anticoagulation. Recurrent PE despite optimized treatment is a selected, weak-guideline option after confirming recurrence, adherence, dose and interactions. Remove a retrievable filter when protection is no longer needed and anticoagulation is tolerated.[2]
Risk Factors
Major surgery (particularly pelvic and orthopedic), hospitalization or immobilization, trauma or fracture, active cancer, pregnancy and the postpartum period, exogenous estrogen, acute medical illness and central venous catheters are the usual provoking factors. Older age, obesity, antiphospholipid syndrome, prior or family VTE and chronic inflammatory disease persist. Inherited thrombophilia may affect extended anticoagulation decisions when PE has no major reversible trigger.[1] Isolated heterozygous factor V Leiden or prothrombin variants usually do not alter duration, whereas antithrombin, protein C and protein S deficiencies are linked to higher recurrence and may affect extended treatment; routine testing is not recommended after PE provoked by major surgery.[2] Extended prophylaxis after pelvic oncology surgery is covered in Antithrombotic Therapy.
Follow-Up and Persistent Symptoms
Arrange contact or a visit within one week after discharge and reassessment by three months. Review medication access and adherence, bleeding, recurrence symptoms, recovery and treatment duration. Ask about functional limitation and persistent dyspnea at follow-up for at least one year.[2]
Persistent symptoms after at least three months of effective treatment warrant evaluation for post-PE problems, including chronic thromboembolic pulmonary disease with or without pulmonary hypertension. Testing is directed by the clinical picture, often including echocardiography and perfusion imaging, with referral to a specialist center when indicated. Do not diagnose CTEPH from an isolated pressure estimate or repeat CTPA routinely in every asymptomatic survivor.[2] CTEPH develops in a low single-digit percentage of PE survivors; pulmonary thromboendarterectomy can be curative in anatomically suitable patients.[23]
References
1. Freund Y, Cohen-Aubart F, Bloom B. Acute pulmonary embolism: a review. JAMA. 2022;328:1336–1345. doi:10.1001/jama.2022.16815
2. Creager MA, Barnes GD, Giri J, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN guideline for the evaluation and management of acute pulmonary embolism in adults. Circulation. 2026;153:e977–e1051. doi:10.1161/CIR.0000000000001415
3. Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311:1117–1124. doi:10.1001/jama.2014.2135
4. Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol. 2017;70:2411–2420. doi:10.1016/j.jacc.2017.09.024
5. ELIQUIS (apixaban). US prescribing information. DailyMed label.
6. XARELTO (rivaroxaban). US prescribing information. DailyMed label.
7. Castellucci LA, et al. Bleeding risk with apixaban vs. rivaroxaban in acute venous thromboembolism. N Engl J Med. 2026. doi:10.1056/NEJMoa2510703
8. COBRRA trial, NCT03266783. Registered eligibility and trial record.
9. Mahé I, Carrier M, Didier R, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N Engl J Med. 2025;392:1363–1373. doi:10.1056/NEJMoa2416112
10. API-CAT trial, NCT03692065. Registered eligibility and trial record.
11. Couturaud F, et al. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet. 2025;405:725–735. doi:10.1016/S0140-6736(24)02842-3
12. Goldberg JB, Giri J, Kobayashi T, et al. Surgical management and mechanical circulatory support in high-risk pulmonary embolisms: AHA scientific statement. Circulation. 2023;147:e628–e647. doi:10.1161/CIR.0000000000001117
13. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370:1402–1411. doi:10.1056/NEJMoa1302097
14. Rosenfield K, et al. Ultrasound-facilitated, catheter-directed fibrinolysis for acute pulmonary embolism. N Engl J Med. 2026. doi:10.1056/NEJMoa2516567
15. HI-PEITHO trial, NCT04790370. Registered eligibility and trial record.
16. van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2017;390(10091):289-297. doi:10.1016/S0140-6736(17)30885-1
17. Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015;36(10):605-614. doi:10.1093/eurheartj/ehu218
18. Jaber WA, Gonsalves CF, Stortecky S, et al. Large-bore mechanical thrombectomy versus catheter-directed thrombolysis in the management of intermediate-risk pulmonary embolism: primary results of the PEERLESS randomized controlled trial. Circulation. 2025;151(5):260-273. doi:10.1161/CIRCULATIONAHA.124.072364
19. Lookstein RA, Konstantinides SV, Weinberg I, et al. Randomized controlled trial of mechanical thrombectomy with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism: primary outcomes from the STORM-PE trial. Circulation. 2026;153(1):21-34. doi:10.1161/CIRCULATIONAHA.125.077232
20. ACTIVASE (alteplase). US prescribing information. DailyMed label.
21. SAVAYSA (edoxaban). US prescribing information. DailyMed label.
22. PRADAXA (dabigatran etexilate). US prescribing information. DailyMed label.
23. Luijten D, Talerico R, Barco S, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: an updated systematic review and meta-analysis. Eur Respir J. 2023;62(1):2300449. doi:10.1183/13993003.00449-2023
24. Singh T, Lavikainen LI, Halme ALE, et al. "Timing of symptomatic venous thromboembolism after surgery: meta-analysis." Br J Surg. 2023;110(5):553-561. doi:10.1093/bjs/znad035
25. Kline JA, Courtney DM, Kabrhel C, et al. "Prospective multicenter evaluation of the pulmonary embolism rule-out criteria." J Thromb Haemost. 2008;6(5):772-780. doi:10.1111/j.1538-7836.2008.02944.x